Table 1 Preclinical data with NCV
From: The perfect personalized cancer therapy: cancer vaccines against neoantigens
Type of neoantigen vaccine | Formulation | Type of Tumor | Checkpoint Inhibitor Blocked | Anti tumor effects | Ref |
|---|---|---|---|---|---|
peptides | poly(I:C) | melanoma | – | tumor delay | [20] |
peptides | anti-CD40 antibody + poly(I:C) | Colon and prostate | – | tumor delay | [23] |
peptides | – | Fibrosarcoma | – | tumor delay | [25] |
peptides | poly(I:C) | Sarcoma | anti PD-1 | tumor delay | [63] |
peptides | poly(I:C) | sarcoma | – | tumor delay | [27] |
RNA and peptides | RNA complexed with cationic lipids | Colon, melanoma, mammary carcinoma | – | tumor delay | [22] |
RNA | RNA complexed with cationic lipids | Colon | – | tumor delay | [28] |
peptides | poly(I:C) | ovary | – | No efficacy | [30] |
peptides | lipoprotein-mimicking nanodiscs | colon, melanoma | anti PD-1 | tumor delay and tumor eradication | [29] |
Long peptides | poly(I:C) | Head and neck cancer | – | tumor delay | [31] |